Drug General Information
Drug ID	D0S2BV
Former ID	DNC000694
Drug Name	Glitazone
Drug Type	Small molecular drug
Indication	Discovery agent		Phase 4	[522750]
Structure		Download 2D MOL 3D MOL
Formula	C10H9NO3S
CAS Number	CAS 2295-31-0
PubChem Compound ID	10198397
Target and Pathway
Target(s)	Peroxisome proliferator activated receptor gamma	Target Info	Agonist	[534997]
KEGG Pathway	PPAR signaling pathway
	AMPK signaling pathway
	Osteoclast differentiation
	Huntington's disease
	Pathways in cancer
	Transcriptional misregulation in cancer
	Thyroid cancer
NetPath Pathway	IL1 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
	Leptin Signaling Pathway
PANTHER Pathway	CCKR signaling map ST
Pathway Interaction Database	Noncanonical Wnt signaling pathway
	Calcineurin-regulated NFAT-dependent transcription in lymphocytes
	Signaling events mediated by HDAC Class I
	RXR and RAR heterodimerization with other nuclear receptor
	Regulation of retinoblastoma protein
Reactome	PPARA activates gene expression
	Transcriptional regulation of white adipocyte differentiation
	Nuclear Receptor transcription pathway
WikiPathways	Wnt Signaling Pathway Netpath
	Nuclear Receptors in Lipid Metabolism and Toxicity
	Differentiation of white and brown adipocyte
	Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Transcriptional Regulation of White Adipocyte Differentiation
	Adipogenesis
	SREBP signalling
	Nuclear Receptors
References
Ref 522750	ClinicalTrials.gov (NCT00953498) Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins. U.S. National Institutes of Health.
Ref 534997	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.